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Introduction: Cardiac toxicity is one of the life-threatening complications of cancer therapy. Systemic
anticancer treatments may exert their own toxic effects or can aggravate adverse effects of other drugs. We
report a case of cyclophosphamide-induced cardiotoxicity in a patient with normal cardiac functions before
chemotherapy.
Case presentation: A 66-year-old Caucasian woman with a mediastinal mass diagnosed with Burkitt lymphoma
underwent chemotherapy with rituximab-hyperfractionated-cyclophosphamide-vincristine-doxorubicin-dexamethasone.
On the seventh day of chemotherapy, she developed dyspnea. An electrocardiogram demonstrated low voltage in the
limb and precordial leads. It also showed diffusely increased myocardial echogenicity, mild pericardial and pleural
effusion, generally impaired biventricular systolic functions with a left ventricular ejection fraction of 31%, and right
ventricular mid-apical akinesia, even though she had normal biventricular functions before chemotherapy.
Cyclophosphamide-induced cardiotoxicity was suspected and she was given treatment for congestive heart
failure. Her dyspnea decreased and she was discharged on the tenth day with a left ventricular ejection fraction
of 37% and normal right ventricular function. After 1 month, echocardiography showed normal biventricular
functions with a left ventricular ejection fraction of 60%.
Conclusions: Drug-induced cardiotoxicity, therefore, should be taken into consideration when using
cyclophosphamide therapy, especially when anthracyclines are co-administered. Close communication between
hematologists and cardiologists is required.
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Cardiac toxicity is one of the life-threatening complica-
tions of cancer therapy. Systemic anticancer treatments
may exert their own toxic effects or can aggravate the
adverse effects of other drugs. Cyclophosphamide-induced
cardiotoxicity (CIC) is a well-known adverse effect and
not that uncommon [1]. Symptoms occur usually within 1
to 3 weeks, and although in some patients cardiotoxicity
resolves without late consequences, the mortality rate
can be as high as 43% [2-4]. Drug side effects are usually
seen after a single administration. Previous and/or
contaminant anthracycline treatment, previous radi-
ation, age older than 50 years, and the presence of
left ventricular (LV) dysfunction [1,4] are the risk* Correspondence: f_noyan@yahoo.com
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unless otherwise stated.factors of drug-induced cardiotoxicity. We report a
case of CIC in a patient with normal cardiac functions
before chemotherapy.Case presentation
A 66-year-old Caucasian woman with a history of hyper-
tension was admitted to our hospital with a recent diagno-
sis of Burkitt lymphoma. Her lactate dehydrogenase level
was high and the diameter of her mediastinal mass was
more than 10cm. Her physical examination was normal,
and basal electrocardiography (ECG) showed sinus rhythm
with a heart rate of 72 beats/minute. Two-dimensional
transthoracic echocardiography (TTE; Siemens, Acuson
Sequoia, C512) revealed normal biventricular functions
with an LV ejection fraction (LVEF) of 60%, mild mitral
and tricuspid regurgitation, and moderate pericardial
effusion.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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category and she underwent rituximab-hyperfractionated-
cyclophosphamide-vincristine-doxorubicin-dexamethasone
(R-Hyper-CVAD) chemotherapy protocol. Her laboratory
values are summarized in Table 1. She received high-dose
cyclophosphamide 300mg/m2 twice daily for 3 days, doxo-
rubicin 25mg/m2/day for 2 days, rituximab 375mg/m2/day
for 1 day, dexamethasone 40mg/day for 4 days, and
vincristine 2mg/day for 2 days. The total treatment dose
of cyclophosphamide and doxorubicin received was
1800mg/m2 and 50mg/m2, respectively. She was given
allopurinol 300mg/day perorally, sodium bicarbonate
(8.4%, 10 flacon/day) infusion for 24 hours before chemo-
therapy, and mesna 600mg/m2/day for 2 days as prophy-
laxis against tumor lysis syndrome and hemorrhagic
cystitis, respectively. She also received granisetron 2mg/day
and lansoprazole 30mg/day as antiemetogenic and gastric
prophylaxis, respectively.
The patient developed dyspnea on the seventh day of
therapy. A physical examination revealed blood pressure
of 100/60mmHg and a heart rate of 110 beats/minute.
On chest auscultation, no inspiratory sounds were heard
at lower zones and inspiratory crackles were heard at
middle zones. Neither cardiac murmurs nor S3 were
heard. An ECG showed low voltage in the limb and pre-
cordial leads. TTE showed diffusely increased myocar-
dial echogenicity, mild pericardial effusion, and generally
impaired biventricular systolic functions with an LVEF
31% and right ventricular mid-apical akinesis. Manifest
pleural effusion was also detected. Drug-induced car-
diotoxicity (myocarditis) was suspected. Furosemide and
ramipril were started. The beta-blocker therapy the pa-





Hemoglobin, g/dL 13 13.1
White blood cell, μL 5750 10,000
Neutrophil, μL 5160 6300
Platelet, μL 201,000 189,000
AST, U/L 24 26
LDH, U/L 535 329
BUN, mg/dL 10 12
Creatinine, mg/dL 0.42 0.37
Calcium, mg/dL 10 9.8
Potassium, mmol/L 4.4 4.5
Uric acid, mg/dL 3.5 3.2
CRP, mg/dL 2.8 71.6
Abbreviations: AST, aspartate transaminase; BUN, blood urea nitrogen;
CRP, C-reactive protein; LDH, lactate dehydrogenase.After 12 days, TTE showed an LVEF of 37% and normal
right ventricular functions. Her dyspnea decreased
and she was discharged on day 20. After 1 month, TTE
showed normal biventricular functions with an LVEF of
60%.
After the first course of the R-Hyper-CVAD chemothe-
rapy protocol, she underwent a high-dose methotrexate
and cytarabine cycle. She had severe neutropenia and
pneumonia. She had no cardiac failure symptoms during
this chemotherapy course, but she declined another
course of chemotherapy. She is still in remission despite
the abbreviated course of chemotherapy.
Discussion
Although progress has been made in therapeutic mo-
dalities of neoplastic diseases with a subsequent im-
provement in mortality and morbidity, life-threatening
toxicities, especially cardiotoxicity, resulting from chemo-
therapy protocols remain a problem. Detection of cardiac
injury after chemotherapy is crucial in order to start treat-
ment as early as possible. Drug-related cardiac toxicity has
been associated mostly with cyclophosphamide-containing
regimens [4].
CIC usually occurs within 1 to 3 weeks, but no definite
risk factors have yet been identified [5]; however, risk ap-
pears to be related to single dose rather than cumulative
drug dose, older age, previous or concomitant use of
anthracycline, and prior mediastinal irradiation [5]. The
pathomechanism of CIC involves direct endocardial in-
jury, followed by extravasation of toxic metabolites resul-
ting in damage to cardiomyocytes, interstitial hemorrhage,
and edema [1,4]. The incidence of fulminant congestive
heart failure is reported to be 5% to 19% [4,6]. Symptoms
may include arrhythmias, acute fulminant heart failure,
myopericarditis, pericardial effusion, cardiac tamponade,
and even death.
The incidence of anthracycline-induced cardiotoxicity
(AIC) varies from 4% to 36% depending on cumulative
dose for doxorubicin [5]. AIC has been categorized as
acute, early-onset chronic progressive, and late-onset
chronic progressive. It presents as dilated cardiomyopathy
with a cardiac morbidity of 1% to 4% in the acute and sub-
acute forms. Acute cardiotoxicity occurs during or shortly
after the infusion with an incidence of <1%, and involves
arrhythmias, heart failure, pericarditis-myocarditis syn-
drome, and nonspecific ST-T changes, which are usually
reversible. Subacute cardiac toxicity occurs within a few
weeks, clinically resembles myocarditis, and has an associa-
ted 60% mortality. Clinically, the most significant cardiac
toxicity of the anthracyclines leading to LV dysfunction is
late cardiac toxicity related to the cumulative anthracycline
dose. Risk factors for anthracycline cardiotoxicity include
cumulative dose; intravenous high single dose; elderly age;
female gender; use of other concomitant agents such as
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tinal irradiation; and underlying cardiovascular disease [5].
Rituximab-related cardiotoxicity is usually in the form
of arrhythmias, reported as 8% in patients treated for
lymphoma. Interleukin-6, tumor necrosis factor-alpha,
and other cytokines released after rituximab use may lead
to cardiac arrhythmias, vasoconstriction, platelet activa-
tion, and/or rupture of atherosclerotic plaque [7,8]. In
treatment of diffuse large B-cell lymphoma, addition of
rituximab to cyclophosphamide-doxorubicin-vincristine-
prednisolone (CHOP) chemotherapy regimen did not
change the cardiotoxicity risk [9].
The only medical history of our patient was hyperten-
sion. She was receiving metoprolol as an antihypertensive
treatment and no another medication. Her cardiac eva-
luation before chemotherapy was applied and there were
no cardiac failure symptoms and findings in her physical
examination, despite mild mitral and tricuspid regurgita-
tion and moderate pericardial effusion. Her total cyclo-
phosphamide dose was 56mg/kg for 3 days, which is not a
high-dose cyclophosphamide regimen (120 to 200mg/kg)
[2]. She also received anthracycline 50mg/m2, again within
safe limits for cardiac toxicity. In addition, she received
Hyper- CVAD chemotherapy protocol with rituximab. Be-
cause the total cumulative dose of anthracycline, the best
predictor of AIC, she received is within normal limits and
acute and subacute forms of AIC are rare, generally minor,
and reversible, we ruled out the diagnosis of AIC. Because
of the timing of cardiotoxicity and its relation to a single
dose, she was diagnosed with CIC.Conclusions
Early detection and management of heart failure after a
chemotherapy regimen is difficult. Cardiac functions should
be assessed at baseline with TTE, even in asymptomatic
patients, before starting combination therapy for cancer.
Repeat assessments, during and after treatment, should also
be considered. Cardiac monitoring with ECG and TTE is
important in detecting clinical signs of cardiotoxicity. Drug-
induced cardiotoxicity should be kept in mind while using
cyclophosphamide therapy, especially when anthracyclines
are coadministered. Close communication between hema-
tologists and cardiologists is required.Consent
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